Jeff recently spoke with Pulitzer-prize winning journalist Kathleen Gallagher on her podcast “How Did You Do That?”, discussing his expansive career in life sciences…
Jeff Aronin discusses why Paragon Biosciences’ unique company incubator approach results in an 80%–90% approval rate on new drug applications, far exceeding that of the traditional pharma industry. Read more about Jeff Aronin’s take on…
June 11, 2021
Chicago is in the midst of a biotech influx, with expansive lab space planned for development. The recent growth can be largely attributed to a year focused on science and medical advancement due to the…
July 23, 2020
Evozyne, a portfolio company of Paragon Biosciences, announced that a peer-reviewed publication in the journal Science…
June 11, 2021
Chicago is in the midst of a biotech influx, with expansive lab space planned for development. The recent growth can be largely attributed to a year focused on science and medical advancement due to the…
July 23, 2020
Evozyne, a portfolio company of Paragon Biosciences, announced that a peer-reviewed publication in the journal Science…
June 23, 2020
The latest edition of Insights Success magazine highlights the efforts of Jeff Aronin, Paragon Biosciences chairman and CEO, to build innovative life science companies…
June 6, 2019
Jeff Aronin, who is the founder, chairman and CEO of Paragon Biosciences, spoke with Chief Executive about why healthcare is stagnant from an innovation standpoint…
